Tag: Nasal high flow therapy
F&P sees increased demand due to COVID-19 surges
January 22, 2021HME News Staff
AUCKLAND, New Zealand – Fisher & Paykel Healthcare reports operating revenue for the nine months ended Dec. 31, 2020, was up 73% in constant currency compared to the prior comparable period.
In the hospital product group, operating revenue was up 113%, with hardware growing 446% and consumables growing 54%.
“In many parts of the world, we have continued to see an influx of COVID-19 patients requiring hospitalization for respiratory treatment,” said Lewis Gradon,...
Coronavirus, Financial Results, Fisher & Paykel Healthcare, Nasal high flow therapy, Obstructive Sleep Apnea (OSA), Pandemic, Sleep Therapy
Sponsored Stories
How Advanced Diabetes Supply is Driving Value-Based Health Outcomes
By Advanced Diabetes SupplySOS Achieves Remarkable 400% Growth in 2023, Bolsters Team with Director Appointment
By Strategic Office SupportCyber Siege: The Financial Vulnerability Healthcare Didn't See Coming
By Strategic Office SupportA new staffing model that delivers ready-to-work pros, boosting efficiency and lowering costs.
By Tactical Back Office